TY - JOUR T1 - Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2022-002587 VL - 8 IS - 2 SP - e002587 AU - Michael DiIorio AU - Kevin Kennedy AU - Jean W Liew AU - Michael S Putman AU - Emily Sirotich AU - Sebastian E Sattui AU - Gary Foster AU - Carly Harrison AU - Maggie J Larché AU - Mitchell Levine AU - Tarin T Moni AU - Lehana Thabane AU - Suleman Bhana AU - Wendy Costello AU - Rebecca Grainger AU - Pedro M Machado AU - Philip C Robinson AU - Paul Sufka AU - Zachary S Wallace AU - Jinoos Yazdany AU - Monique Gore-Massy AU - Richard A Howard AU - More A Kodhek AU - Nadine Lalonde AU - Laura-Ann Tomasella AU - John Wallace AU - Akpabio Akpabio AU - Deshiré Alpízar-Rodríguez AU - Richard P Beesley AU - Francis Berenbaum AU - Inita Bulina AU - Eugenia Yupei Chock AU - Richard Conway AU - Alí Duarte-García AU - Eimear Duff AU - Tamer A Gheita AU - Elizabeth R Graef AU - Evelyn Hsieh AU - Lina El Kibbi AU - David FL Liew AU - Chieh Lo AU - Michal Nudel AU - Aman Dev Singh AU - Jasvinder A Singh AU - Namrata Singh AU - Manuel F Ugarte-Gil AU - Jonathan S Hausmann AU - Julia F Simard AU - Jeffrey A Sparks Y1 - 2022/09/01 UR - http://rmdopen.bmj.com/content/8/2/e002587.abstract N2 - Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs).Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression.Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81).Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.Data are available on reasonable request. Researchers interested in performing additional analyses from survey data are invited to submit proposals through the COVID-19 Global Rheumatology Alliance at rheum-covid.org. For approved projects, we will be able to provide summary tables and data analyses as requested. We do not currently have institutional review board approval to make the raw data available to other researchers. ER -